In a call with investors after the results were announced, Martin Lange, executive vice president of R&D, chief scientific officer and member of the Management Board for Novo Nordisk, explained that Zepbound performed unusually well on efficacy compared to what has typically been reported in most previous trials of a similar nature. In a phase 3 trial in adults with pre-diabetes and obesity, participants had an average weight reduction of 22.9% on the highest dose of tirzepatide, 2.1% less weight loss than was seen in the CagriSema comparator trial
The Success by Sesame program starts at just $59 per month with an annual subscription and includes telehealth visits, unlimited messaging, and ongoing clinical care from a provider of your choice
GLP-1s can drive up costs significantly even when prescribed to a relatively small percent of employees
Maiseyeu A, Di L, Ravodina A, Barajas-Espinosa A, Sakamoto A, Chaplin A, et al